Clinical Trial Update: Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy [Phase 3]

View source ↗

Summary

A Phase 3 safety study evaluating immune responses to vaccines in relapsing forms of multiple sclerosis in participants receiving ozanimod versus non-pegylated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Interferon-beta (interferon beta)
• Ozanimod (ozanimod)

Snippet

Sponsor: Celgene | Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2025-01-22